AREV Life Sciences Global Corporation Announces Engagement of TransBIOTech to Facilitate Development of Preclinical Therapeutic Pipeline
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) — via InvestorWire — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV » or the “Company”) today announced its initial research engagement with TransBIOTech.
Founded in 1999, TransBIOTech is a public preclinical research organization that works in partnership and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (NSERC) in collaboration with the Institutes of Health Research of Canada (CIHR). TransBIOTech is also supported by the Canadian Foundation for Innovation and by the Government of Quebec. TransBIOTech is a member of Tech-Access Canada, a national organization of Technology Access Centers (CAT), as well as a member of Synchronex, a network of College Centers for Technology Transfer (CCTT) in Quebec. The TransBIOTech laboratory uses more than $16 million in state-of-the-art equipment and offers an animal facility accredited by the Council on Animal Care of Canada (source: https://www.tbt.qc.ca/fr/installations/).
TransBIOTech is a multi-sectional research center with expertise in the life sciences sector, specializing in analytical chemistry, biochemistry, cellular and molecular biology and microbiology for pharmaceutical sciences. TransBIOTech has capabilities in various project stages, including in vitro, in cellulo and in vivo functional assays (biomarkers, cytotoxicity, anti-inflammatory properties and antimicrobial activity, as well as analysis of the pharmacological properties of molecules, including the permeability, metabolic stability, ADME and toxicology).
“TransBIOTech engages with AREV in its initial cannabinoid research and other early-stage commercial research programs. Our agreement with TransBIOTech signals the launch of a robust clinical initiative with numerous collaborators to facilitate data on some of the most promising phytomedicinal therapeutics currently relevant today.‘s public health challenges,” said AREV CEO Mike Withrow.
Withrow also said, “AREV Life Sciences is committed to strengthening its scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovations relevant to contemporary pandemic infectious diseases and human nutrition. By leveraging our proprietary extraction technologies combined with the discovery capabilities of TransBIOTech and other reputable research institutes, we are laying the foundation for initial animal studies to identify datasets that will satisfy regulatory authorities.
Recent preclinical studies have claimed that CBD modulates anti-inflammatory effects. Clinical studies have verified that CBD lowers levels of pro-inflammatory cytokines, suppresses T-cell proliferation, creates T-cell apoptosis, and reduces immune cell migration and adhesion. It has also been discovered that this CBD-induced anti-inflammatory action appears to be antagonized by both a CB2 antagonist and a CB2 receptor agonist (source: https://www.frontiersin.org/articles/10.3389/fphar.2017.00144/full). The TransBIOTech collaboration with AREV will also examine the precise mechanisms of action attributed to the activation of CB2 as a new therapeutic modality modulating the inflammation characteristic of viral infections (source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005548/).
The collaboration between AREV and TransBIOTech will facilitate the further development of proprietary immunomodulatory therapies derived from phytomedical research that treat pandemic infectious diseases affecting host responses to elevated cytokine expression.
Initial studies will lay the groundwork for advancing research, enabling a distinct understanding of AREV‘s the development of new chemical entities, including initial toxicity, pharmacokinetics and metabolism modeling, essential for human studies and eventual commercialization. Reduction of pathogen-mediated inflammation and subsequent immune hyperactivation by inhibiting the progression of mTOR/S6K signaling, which is affected by the cannabinoid receptor CB1, also prevents Jurkat cells from expressing the regulation of immune responses (source: https://www.nature.com/item/4401660). In vivo studies have demonstrated that mTOR expression is affected by cannabinoid regulatory mechanisms leading to autophagy in cancer cell pathways necessary for antitumor actions (source: https://www.jci.org/articles/view/37948).
AREV, in collaboration with TransBIOTech, is also designing preclinical characterization studies to identify suspected therapeutic characteristics of other compounds of botanical origin identified in the peer-reviewed literature, including phytocannabinoids and Cucumaria frondosa, leading to small molecule candidates for human studies.
Edouard Lauzer, from TransBioTech, said: “Our preclinical characterization research with TransBIOTech is an important step for AREV.‘s efforts to provide well-defined clinical insights into the multidimensional aspects of immune modulation associated with CBD and other compounds derived from phytomedicinal drug development. AREV‘TransBIOTech’s efforts will include the characterization of CBD’s mechanism of action as well as the analysis of structure-activity relationships of secondary metabolites through the discovery of fragment-based leads and de novo drug design, using high-throughput screening to identify structural-functional relationships of AREV‘s investigational compounds affecting pathogen-mediated inflammation and viral replication.
The initial studies designed by TransBIOTech, in collaboration with members of AREV’s Scientific Advisory Board (SAB), will provide correspondence of subsequently published results from these studies to public research programs, including the National Institute of Health.‘s Accelerating COVID-19 Therapeutic Interventions and Vaccines (NIH ACTIV), AIDS Clinical Trial Groups (NIAID ACTGs) of the National Institute of Allergy and Infectious Diseases and President Biden‘s White House Cancer Cabinet.
On behalf of the Council,
CEO and Director
ABOUT AREV Life Sciences Global Corp.
AREV Life Sciences Global Corp. is a fully integrated, publicly traded, early-stage life sciences company with a U.S. subsidiary dedicated to delivering therapeutic public health interventions through unique compound extraction, discovery, innovation and fruitful collaborations. The company’s leadership drives discovery programs for the clinical complexities presented by malnutrition, viral infectious diseases and elevated inflammatory responses. AREV invests in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for the associated chronic neglected comorbidities and innovations in human nutrition. In addition to its program of phytomedicinal discoveries, AREV is developing a new generation Ready-to-Use Therapeutic Food (RUTF). SUSTAINN is designed by AREV in collaboration with the Richardson Center for Functional Foods and Nutraceuticals at the University of Manitoba which demonstrates clinical attributes addressing severe acute malnutrition (SAM). AREV is dedicated to designing and delivering innovations in rational drug design, driven by presenting the global epidemiological characteristics of the multiple challenges in international human and animal health. AREV is a member of BIOTECanada and the Biotechnology Innovation Organization (BIO).
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, goals, assumptions, expectations or beliefs, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “anticipates”, “expects” or “does not expect”, “is planned”, “estimates”, “intends” , “anticipates” or “does not anticipate”, “or “believes”, or variations of these words and phrases or statements that certain actions, events or results “could”, “could”, “might”, “might” or “will” be taken, occur or be achieved. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
THE CSE HAS NEITHER APPROVED OR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND ACCEPTS NO RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.